Key result
Statin therapy duration of less than 20 years was an independent predictor of failure of statin discontinuation compared to 20 years or more in lymphoma patients aged 80 years and older.
Why the study?
Evidence supporting or negating the benefits of statin therapy for primary prevention of cardiovascular disease in lymphoma patients aged 80 years or older is limited.
Does duration of prior statin therapy predict failure of statin discontinuation in lymphoma patients aged 80 years and older?
Cohort (n=50)
No
Does duration of prior statin therapy predict failure of statin discontinuation in lymphoma patients aged 80 years and older?
In lymphoma patients aged 80 years and older, statin therapy discontinuation is more likely to be successful without reintroduction if the patient has been on statins for 20 years or more.
Answers are grounded in this paper and cite their sources.
May guide statin deprescribing in very elderly lymphoma patients; leaves open net clinical benefit of discontinuation.
BACKGROUND: There is little evidence to support or negate the benefits of statin therapy for primary prevention of cardiovascular disease (CVD) in lymphoma patients aged 80 years or older. OBJECTIVE: We evaluated comprehensive geriatric assessment (CGA) scores and previously reported risk factors for failure of statin therapy discontinuation in lymphoma patients aged 80 years and older with the aim of identifying those in whom discontinuation of statins for primary CVD prevention is indicated. PATIENTS AND METHODS: Our study cohort comprised 50 patients aged 80 years and older treated with chemotherapy for lymphoma at our institute from January 2011 to July 2020. We retrospectively analyzed the associations between CGA, including Geriatric 8, instrumental activities of daily living, and Charlson comorbidity index, and previously reported factors associated with failure of statin therapy discontinuation, defined as reintroduction of statins after their discontinuation, in this patient cohort. RESULTS: Twenty years or less of statin therapy was an independent predictor of failure of statin therapy discontinuation (hazard ratio 8.240, 95% confidence interval 1.380-49.10). There were significant differences in the rate of failure of statin discontinuation between patients receiving statins for ≥ 20 years versus < 20 years (p = 0.010). Multivariate analysis of CGA-related scores identified no significant risk factors for failure of statin discontinuation. CONCLUSIONS: Discontinuation of statin therapy may be indicated in lymphoma patients aged 80 years and older who have used statins for 20 years or more.
No takes yet. Share an insight, caveat, or question.
Yamasaki et al. (2022) conducted a cohort in Lymphoma (n=50). Statin therapy duration < 20 years vs. Statin therapy duration ≥ 20 years was evaluated on Failure of statin therapy discontinuation (reintroduction of statins) (HR 8.240, 95% CI 1.380-49.10, p=0.020). Statin therapy duration of less than 20 years was an independent predictor of failure of statin discontinuation compared to 20 years or more in lymphoma patients aged 80 years and older.
Synapse has enriched 10 related papers. Consider them for comparative context: